News

MST Access has initiated coverage of Race Oncology with a current $4.88 per share valuation. The full report can be downloaded below. MST Access - RAC Initiation - 18 Feb…

Race Oncology Limited (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM). https://www.youtube.com/watch?v=J7WKOtMEPnI Race's Managing Director and CEO, Mr Phil…

Race Oncology is pleased to release our updated strategic plan for the clinical advancement of Bisantrene at our 2020 AGM. The recent identification of Bisantrene as a potent inhibitor of…

10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and…

5 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and…